Nikko Asset Management Americas, Inc. Crispr Therapeutics Ag Transaction History

Nikko Asset Management Americas, Inc.

$7.42 Billion
Q1 2025

A detailed history of Nikko Asset Management Americas, Inc. transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Nikko Asset Management Americas, Inc. holds 2,539,889 shares of CRSP stock, worth $141 Million. This represents 1.16% of its overall portfolio holdings.

Number of Shares

2,539,889

Previous 2,745,676 7.49%

Holding current value

$141 Million

Previous $108 Million 20.02%

% of portfolio

1.16%

Previous 1.21%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 07, 2025	SELL	$34.03 - $53.02 $7 Million - $10.9 Million	-205,787 Reduced 7.49%	2,539,889 $86.4 Million
Q4 2024 Feb 10, 2025	SELL	$38.65 - $55.15 $8.56 Million - $12.2 Million	-221,543 Reduced 7.47%	2,745,676 $108 Million
Q3 2024 Nov 07, 2024	SELL	$44.62 - $62.75 $8.22 Million - $11.6 Million	-184,295 Reduced 5.85%	2,967,219 $139 Million
Q2 2024 Aug 09, 2024	SELL	$51.17 - $68.18 $6 Million - $8 Million	-117,271 Reduced 3.59%	3,151,514 $170 Million
Q1 2024 May 02, 2024	SELL	$60.67 - $89.12 $6.13 Million - $9 Million	-100,977 Reduced 3.0%	3,268,785 $223 Million
Q4 2023 Feb 08, 2024	SELL	$38.62 - $72.18 $3.7 Million - $6.91 Million	-95,708 Reduced 2.76%	3,369,762 $211 Million
Q3 2023 Nov 09, 2023	SELL	$45.39 - $59.0 $3.08 Million - $4.01 Million	-67,887 Reduced 1.92%	3,465,470 $157 Million
Q2 2023 Aug 14, 2023	SELL	$43.47 - $67.77 $19.1 Million - $29.7 Million	-438,782 Reduced 11.05%	3,533,357 $198 Million
Q1 2023 May 03, 2023	SELL	$41.0 - $56.12 $1.41 Million - $1.93 Million	-34,337 Reduced 0.86%	3,972,139 $180 Million
Q4 2022 Feb 13, 2023	SELL	$39.19 - $65.67 $10 Million - $16.8 Million	-256,260 Reduced 6.01%	4,006,476 $163 Million
Q3 2022 Nov 14, 2022	SELL	$61.1 - $83.78 $19.6 Million - $26.9 Million	-321,362 Reduced 7.01%	4,262,736 $277 Million
Q2 2022 Aug 04, 2022	SELL	$43.23 - $73.83 $1.54 Million - $2.63 Million	-35,649 Reduced 0.77%	4,584,098 $276 Million
Q1 2022 May 06, 2022	BUY	$53.19 - $79.24 $16 Million - $23.8 Million	300,276 Added 6.95%	4,619,747 $291 Million
Q4 2021 Feb 08, 2022	BUY	$70.09 - $111.29 $72.2 Million - $115 Million	1,029,955 Added 31.31%	4,319,471 $331 Million
Q3 2021 Nov 09, 2021	SELL	$110.2 - $156.64 $10.4 Million - $14.7 Million	-93,940 Reduced 2.78%	3,289,516 $368 Million
Q2 2021 Aug 09, 2021	SELL	$100.84 - $161.89 $27.9 Million - $44.7 Million	-276,409 Reduced 7.55%	3,383,456 $548 Million
Q1 2021 May 03, 2021	SELL	$110.72 - $210.04 $19.6 Million - $37.2 Million	-176,958 Reduced 4.61%	3,659,865 $446 Million
Q4 2020 Feb 11, 2021	BUY	$79.67 - $173.23 $11.1 Million - $24.1 Million	139,156 Added 3.76%	3,836,823 $587 Million
Q3 2020 Nov 02, 2020	SELL	$78.5 - $100.64 $1.12 Million - $1.44 Million	-14,303 Reduced 0.39%	3,697,667 $309 Million
Q2 2020 Aug 07, 2020	SELL	$38.5 - $76.05 $2.1 Million - $4.15 Million	-54,571 Reduced 1.45%	3,711,970 $269 Million
Q1 2020 Apr 30, 2020	BUY	$33.68 - $62.53 $24.1 Million - $44.8 Million	716,988 Added 23.51%	3,766,541 $160 Million
Q4 2019 Feb 06, 2020	BUY	$36.68 - $73.13 $9.98 Million - $19.9 Million	272,139 Added 9.8%	3,049,553 $186 Million
Q3 2019 Oct 29, 2019	BUY	$40.99 - $52.56 $37.1 Million - $47.6 Million	906,006 Added 48.41%	2,777,414 $114 Million
Q2 2019 Jul 29, 2019	BUY	$35.45 - $48.2 $50.7 Million - $68.9 Million	1,430,364 Added 324.31%	1,871,408 $88.1 Million
Q1 2019 Apr 30, 2019	BUY	$28.02 - $40.87 $12.3 Million - $18 Million	440,120 Added 47632.03%	441,044 $15.8 Million
Q4 2018 Feb 08, 2019	SELL	$22.73 - $42.34 $4,546 - $8,468	-200 Reduced 17.79%	924 $26,000
Q3 2018 Oct 15, 2018	BUY	$44.35 - $65.71 $49,849 - $73,858	1,124 New	1,124 $50,000

Others Institutions Holding CRSP

# of Institutions

489

Shares Held

64.5M

Call Options Held

2.16M

Put Options Held

2.1M

View Full List

About CRISPR Therapeutics AG

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $4.34B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

More about CRSP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nikko Asset Management Americas, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Nikko Asset Management Americas, Inc. with notifications on news.

Account

Nikko Asset Management Americas, Inc. Crispr Therapeutics Ag Transaction History